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Abstract
Background: Pregnancy introduces major physiological 
changes that also alter biochemical analytes. Maternal and 
perinatal health can be optimized by early intervention and 
therefore, pregnancy-specific reference intervals (RIs) for 
the local population are warranted. While the second and 
third trimester-specific changes are well described, the first 
trimester is less well characterized. We therefore wanted 
to facilitate early detection of abnormalities by generating 
first trimester reference values for 29 common analytes.
Methods: In a prospective early pregnancy (PEP) cohort 
(2016–2017), 203 pregnant women were recruited from 4 
to 8  weeks’ gestation. Consecutive blood samples were 
drawn every 2  weeks until an ongoing second trimester 
pregnancy (n = 164) or a miscarriage (n = 39) occurred. 
After exclusion of women with complicated pregnancies 
or deliveries (n = 42), 122 women were included. The serum 
samples collected at <6, 6–8, 8–10, 10–12 and >12 weeks’ 
gestation were analyzed for 29 common analytes. Subse-
quently the RIs were calculated according to the Interna-
tional Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) recommendations (2.5–97.5th percentiles) 
and compared with the conventional RIs for non-pregnant 
women.
Results: Human chorionic gonadotropin (hCG), proges-
terone (P4), estradiol (E2), pregnancy-associated plasma 
protein A (PAPP-A), cancer antigen 125 (CA125), thyroid 
stimulating hormone (TSH), creatinine (CREA) and 
albumin (ALB) showed an early pregnancy-dependent 
change compared with conventional limits. For ALB the 
change was seen at 5.5 weeks’ gestation.
Conclusions: We report gestational age-specific RIs avail-
able from the early part of the first trimester applicable to 
everyday clinical care of pregnant women. Well-known 
alterations of RIs seen in later trimesters are also observed 
in the first.
Keywords: first trimester; pregnancy; reference interval; 
reference range; reference value.
Introduction
The first trimester has emerged as an increasingly acces-
sible timespan for developing diagnostic algorithms 
concerning the prevalent diseases of pregnancy, e.g. 
preeclampsia, small-for-gestational age infants and gesta-
tional diabetes mellitus [1–6]. Declared millennium devel-
opmental goals (MDG 4 and 5) [7] by the WHO, and the 
International Federation of Gynecologists and Obstetri-
cians (FIGO) has identified the first trimester as a window 
of opportunity for optimizing both maternal and fetal 
health, especially concerning the prediction and preven-
tion of chronic diseases later in life.
Normal pregnancy and the associated surge of 
reproductive hormones has a major impact on maternal 
physiology as it increases cardiac output, expands the 
vascular compartments and increases stress on the liver 
and kidneys. This marked influence on female physiology 
also leads to alterations of most commonly used biochem-
ical measurands compared with the conventional non-
pregnant reference intervals (RIs) [8–10]. Therefore, the 
clinical care of pregnant women would benefit from reli-
able RIs that take demographic and societal factors such 
as ethnicity, dietary intake and subclinical diseases into 
account [11]. Modern automated equipment has improved 
the intra- and interlaboratory assay variations. However, 
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inter-instrument bias remains a challenging issue in any 
laboratory and uniform translation across different plat-
forms has yet to be attained. It therefore follows that labo-
ratories offering biochemical analyses of pregnant women 
ideally should provide gestational age-specified RIs for all 
relevant analytes across all three trimesters.
Unfortunately, most RIs for pregnant women are 
available from the late first or early second trimester and 
onwards [8–10, 12–14] or are extrapolated from a control 
group of participants in a trial examining a first trimes-
ter complication [10]. Accordingly, such values are not 
ideal for identifying early pregnancy abnormalities and 
often lack the statistical requirements recommended for 
establishing RIs by the International Federation of Clini-
cal Chemistry and Laboratory Medicine (IFCC) [15].
In response to the increased focus on first-trimester 
diagnostics, we therefore established gestational age-
specific serum-based RIs of 29 commonly used clinical 
analytes in an early pregnancy cohort of women that had 
a live birth following an uncomplicated and naturally con-
ceived pregnancy.
Materials and methods
Study population
From June 2016 to March 2017, a prospective early pregnancy cohort 
(the PEP cohort) after natural conception was recruited via online 
add campaigns and subsequently followed at North Zealand Hos-
pital, Hillerød or Rigshospitalet, Copenhagen, Denmark. Following 
a positive urinary pregnancy test, 218 women expressed interest in 
participating and 212 attended the first visit (four lost interest and 
two were not pregnant). As seen in the Figure 1, 210 were included 
in the cohort (two had surpassed the inclusion criterion of no more 
than 55 days’ gestation). Participants were at least 18 years of age, 
able to understand and sign a written consent and had an ultrasoni-
cally confirmed pregnancy with one fetus. Women with a history of 
recurrent pregnancy loss (≥3 consecutive losses), all types of fertility 
treatments, known or initially diagnosed abnormalities of the uterus 
or tubes or an ongoing drug abuse were excluded. All participants 
were followed consecutively with serial blood samples and trans-
vaginal ultrasonography every second week until they either had a 
miscarriage (n = 37) or they completed the first trimester (n = 166). 
Also shown in Figure 1, 203 women were included for analyses after 
exclusion of seven participants due to lost interest (n = 3) and multi-
ple gestation (n = 3). One woman was excluded from the cohort and 
210 women were included
203 women were included in analyses
3 lost interest
3 had multiple gestations
1 withdrew for other reasons
166 completed the first trimester
37 miscarried
2 had a late pregnancy loss
164 had a live birth
122 had uncomplicated pregnancies and
deliveries and were analyzed to establish
reference intervals  
42 had complications
69 had
samples
<6
weeks
121 had
samples
6–8
weeks
119 had
samples
8–10
weeks
94 had
samples
10–12
weeks
63  had
samples
>12
weeks
5 had GDM
7 had hypertension or preeclampsia
6 had thyroid diseases
4 received prescription medication
4 had asthma
7 smoked
6 delivered preterm or had low birthweight
3 had other chronic medical diseases
Figure 1: Flow chart of the selection of participants.
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further blood sampling because her pregnancy developed ultrasoni-
cally resembling an early pregnancy loss. However, continued clini-
cal follow-up later proved a healthy pregnancy.
A pregnancy follow-up of all participants in 2018 recorded 164 
live births (two had late pregnancy loss). Within this group, RIs were 
based on 466 blood samples from 122 women, who fulfilled the cri-
teria of an uncomplicated pregnancy and delivery. As described in 
 Figure 1, exclusion criteria for this study comprised gestational diabe-
tes mellitus, hypertension or preeclampsia, thyroid disease, prescrip-
tion medication, asthma, other chronic medical diseases, smoking, 
preterm or low birthweight infants and 5 min Apgar scores (<7).
Gestational age estimation
All participants had a transvaginal ultrasonography (GE Voluson i 
BT14, GE Healthcare, Solingen, Germany) at each visit. Gestational 
age was determined when a crown-rump-length (CRL) could be 
measured [16]. Due to early inclusion, some participants did not have 
a CRL-measurable fetus from their initial scan, thus their gestational 
age at visit 1 was calculated and registered after visit 2. Therefore, a 
visit 2  with CRL showing 50  days’ gestation meant that a previous 
visit 1, 14 days earlier, without CRL estimation, was set at 36 days’ 
gestation.
Blood samples
Each participant had an 18  mL peripheral blood sample drawn 
from the veins of the antecubital fossa using the Vacutainer serum 
separator tubes (BD Diagnostics, Franklin Lakes, NJ, USA). Fasting 
was not required as it was considered intolerable due to frequent 
nausea in the first trimester. All samples were done from 8 a.m. to 
7 p.m. To allow clotting, the blood was stored at room temperature 
for 15 min before 10 min of 3500 g centrifuge at 5 °C (Hettich Rotina 
380 R, Andreas Hettich GmbH, Tuttlingen, Germany). The separated 
components were finally aliquoted to polypropylene RNase-, DNase-
free microcentrifuge tubes and stored at −80 °C. The samples were 
thawed and analyzed 8 months after the last inclusion to allow for 
appropriate follow up to be completed.
Table 1: Biochemical details of serum analytes.
Analyte (abbreviation) CV% Traceability NPU code
Siemens Dimension Vista 1500 (Siemens Healthcare Diagnostics Inc., Newark, DE, USA)
 Albumin (ALB) 5.8 ERM-DA470k/IFCC NPU19673
 Alkaline phosphatase (ALP) 5.6 IFCC acc. Schumann Gen 2. NPU27783
 Alanine aminotransferase (ALT) 3.8 IFCC NPU19651
 Aspartate aminotransferase (AST) 5.7 IFCC NPU19654
 Lactate dehydrogenase (LDH) 6.7 IFCC 2002 NPU19658
 Bilirubin, total (BIL) 8.5 Doumas candidate reference method NPU01370
 Iron, free (IRON) 4.2 SRM 937 NPU02508
 Ferritin (FTL) 4.4 NIBSC standard 80/602 NPU19763
 Cholesterol (CHOL) 4.2 ID-MS NPU01566
 High-density lipoprotein (HDL) 5.4 Internal NPU01567
 Low-density lipoprotein (LDL) 4.0 Internal NPU01568
 Triglyceride (TRIG) 5.5 ID-MS NPU04094
 Blood urea nitrogen (BUN) 5.5 ID-MS NPU01459
 Creatinine (CREA) 4.7 ID-MS NPU04998
 Sodium (Na) 1.5 NIST SRM929A NPU03429
 Potassium (K) 3.0 NIST SRM928A EPC00026
 Uric acid (URIC) 4.9 ID-MS NPU03688
 Thyroid stimulating hormone (TSH) 6.1 WHO 80/558 2nd IRP NPU03577
 C-reactive protein (CRP) 10.3 Internal method traceable to CRM 470 NPU19748
 Human chorionic gonadotropin, total (hCG) 5.7 IS 75/589; proc NPU01580
 Progesterone, total (P4) 14.5 ID-GC/MS-method NPU03242
 Estradiol (E2) 7.6 ID-GC/MS-method NPU01972
Siemens Centaur XP (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA)
 Triiodothyronine, total (T3) 3.4 Derived from USP material NPU03625
 Triiodothyronine, free (fT3) 4.4 Derived from USP material NPU03625
 Thyroxine, total (T4) 4.4 Derived from USP material NPU03578
 Thyroxine, free (fT4) 4.5 Derived from USP material NPU03579
 Cancer antigen 125 (CA125) 4.6 Derived from an internal standard NPU01448
Kryptor Compact Plus (Thermo Fisher, Nimes, France)
 Human chorionic gonadotropin, free (fhCG) 5 1.st IRP WHO 75/551 NPU01580
 Pregnancy-associated plasma protein A (PAPP-A) 5 Internal reference NPU22157
CV, coefficient of variation; NPU, nomenclature for properties and units.
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Laboratory analysis
All samples were examined at the Department of Clinical Biochem-
istry, North Zealand Hospital. The analytes examined, equipment 
manufacturers and assay coefficients of variation, traceability and 
nomenclature for properties and units (NPU Codes) are listed in 
Table 1.
Albumin (ALB), alkaline phosphatase (ALP), alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), lactate 
dehydrogenase (LDH), total bilirubin (BIL), free iron (IRON), fer-
ritin (FTL), cholesterol (CHOL), high-density lipoprotein (HDL), 
low-density lipoprotein (LDL), triglyceride (TRIG), blood urea 
nitrogen (BUN), creatinine (CREA), sodium (Na), potassium (K), 
uric acid, (URIC), thyroid stimulating hormone (TSH), C-reactive 
protein (CRP), total human chorionic gonadotropin (hCG), total 
progesterone (P4) and estradiol (E2) were analyzed using Siemens 
Dimension Vista 1500. Free and total triiodothyronine (fT3 and T3) 
and thyroxine (fT4 and T4) as well as cancer antigen 125 (CA125) 
were measured by Siemens Centaur XP and pregnancy-associated 
plasma protein A (PAPP-A) and the free beta human chorionic gon-
adotropin (fhCG) using the Kryptor Compact Plus.
Statistical analysis
Conditional quantile regression according to the LMS method [17] 
was performed using R [18] and the package gamlss [19]. The degrees 
of freedom for the spline expansions and a choice between the Box-
Cox t distribution and the Box-Cox normal distribution were selected 
according to the AIC criterion. A non-parametric bootstrap procedure 
with 25,000 resamples was used to estimate 90% overall confidence 
envelopes for the 2.5% and 97.5% conditional quantile functions [20]. 
The envelopes were compared with the corresponding 90% confi-
dence intervals (CIs) of the conventional RI to decide whether and, 
if so, when the pregnancy-dependent interval became approximately 
significantly different. The Reference Intervals, software package 
and an IFCC-recommended approach [15, 21] was used to calculate 
RI including 90% CI for the limits every second week of the obser-
vational period. Outliers were detected according to Horn’s method 
[22] and evaluated with the patient chart. If a value was biologically 
unexplainable, suggesting measurement failure, it was removed. 
All missing data were assumed to be missing complete at random 
(MCAR) [23] due to laboratory processing glitches. Irrespective, all 
values were reported from a complete case analysis as RIs are usually 
not derived from imputed data. When the concentration was equal 
to or below the lower detectable limit of the assay, the value of the 
detection limit was used as a test result. Student’s t-test and the chi-
squared test were used to test for differences in means or proportions, 
respectively, and p-values below 5% were considered statistically sig-
nificant.
Ethics
All participants received oral and written information about 
the study prior to participation and signed an informed consent 
according to the standards of the Helsinki declaration. The study 
was approved by the local Regional Ethical Committee (H15018059) 
as well as the Danish Data Protection Agency (NOH-2015-042) and 
was published at clinicaltrials.org prior to first patient enrollment 
(NCT02761772).
Results
All participants delivered a healthy singleton neonate 
during 2017. Table 2 shows the study population demog-
raphy compared with the 2017 nationwide Danish birth 
data [24]. Participants were younger (mean ± SD; 29 ± 4 vs. 
30 ± 5  years, p = 0.01) due to 62% being <30  years of age 
(46% nationwide, p < 0.001). Participants were less likely 
to be nulliparous (27% vs. 39% nationwide, p = 0.02) and 
birthweights were marginally higher than the nationwide 
mean (3592 ± 457 vs. 3474 ± 609 g, p = 0.005). All partici-
pants were Caucasian.
Table 3 shows RIs (2.5–97.5th percentiles) and the 
90% CI for these limits per 2  weeks’ gestation of each 
analyte. As also shown in Figure 2: ALB, hCG, P4, E2, 
PAPP-A, CA125, TSH and CREA, already exhibited a 
notable change during the earliest part of the first tri-
mester. ALB values reduced almost linearly from a 
starting range (36–48 g/L) equal to the conventional RI 
(37–48 g/L) and finished with the median below the 2.5 
percentile of the conventional (>12 weeks’ RI 31–42 g/L). 
The pregnancy-dependent markers of hCG, fhCG and 
PAPP-A developed expectedly showing surges around 
6–9  weeks’ gestation. hCG plateaus about 9  weeks’ 
gestation before decreasing in the remaining period. 
The P4 and E2 97.5th percentile surpassed the luteal 
phase-based conventional equivalent throughout the 
observation and were both significantly increased after 
4.5 weeks’ gestation. Additionally, the E2 2.5th percen-
tile exceeded the conventional 97.5th at about 8 weeks’ 
and became significantly higher after 11  weeks’ ges-
tation. CA125 levels developed a peak at 6  weeks’ 
gestation (<6  weeks RI 7–170 U/mL) with the 97.5th 
percentile significantly higher already after 4.5 weeks. 
Levels decreased thereafter and at 11  weeks’ gestation 
the 97.5th percentile were within conventional limits. 
TSH described a U-shaped curve with a minimum at 
8–10  weeks’ gestation (0.10–4.1  mU/L) resembling the 
conventional range (0.30–4.0 mU/L). About half of CRP 
values (279/463, 60%) were at the lowest limit of assay 
detection, although a tendency of higher values with 
gestation was seen. Early CREA were marginally higher 
than values by 9 weeks’ gestation (<6 weeks: 42–68 vs. 
8–10 weeks: 39–66 μmol/L) with an almost steady curve 
thereon. Compared with conventional limits, the 97.5th 
percentile was reduced throughout the observation and 
the 2.5th became significant after 4.5 weeks’ gestation.
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As shown in Supplementary Figure 1, other markers 
were either aligned with the conventional RI or rather 
were unchanged during the entire first trimester.
Discussion
This study successfully established detailed RIs for 29 
common analytes in the first trimester of women who 
had a naturally conceived and uncomplicated preg-
nancy with the delivery of a healthy singleton neonate. 
Primarily, the study provided novel and detailed data 
from 4 to 8 weeks’ gestation. This allowed for an assess-
ment of when these analytes deviated from the RIs of 
non-pregnant women and hence could become clinically 
important. Furthermore, by determining the RIs for 29 
biomarkers of endocrine, renal, liver and inflammatory 
function the study provided an overview of the many-
facetted early reprograming of body physiology induced 
by pregnancy.
Endocrine
The production of hCG has been detected in plasma as 
early as 6–14  days after fertilization [25]. In our assay, 
hCG and fhCG were primarily increased after placenta-
tion (week 6), as shown in Figure 2. Hereafter, the pro-
duction increased markedly until week 9. PAPP-A is a 
protease that cleaves IGFBP4 causing the release of IGF1 
and IGF2. PAPP-A, like hCG, are synthesized by the syn-
cytiotrophoblast and secreted into the maternal circula-
tion in increasing concentrations until term [26]. Low 
levels of PAPP-A are therefore associated with restricted 
fetal growth as IGF markedly influence fetal intrauterine 
Table 2: Cohort demographics at the time of inclusion compared with the 2017 nationwide Danish birth data.
  Study population   Danish 2017 births   p-Value
n   122   60,871  
Age, years, mean, SDa   29.3   (4.1)   30.3   (5.0)   0.01
Age groups, n (%)b
  < 30 years   76   (62.3)   27,694   (45.5)   <0.001
 30–35 years   33   (27.0)   23,547   (38.7)  
  > 35 years   13   (10.7)   9630   (15.8)  
BMI, kg/m2, mean, SDa   24.1   (4.4)   24.8   (8.2)   0.07
BMI groups, n (%)b
 Normal weight   76   (62.3)   35,189   (57.8)   0.08
 Underweight   3   (2.5)   2579   (4.2)  
 Pre-obese   34   (27.9)   12,683   (20.8)  
 Obese   9   (7.4)   8009   (13.2)  
 Missing   NA   2411   (4.0)  
Former pregnancies, n (%)b
 0   33   (27.0)   23,637   (38.8)   0.02
 1   42   (34.4)   19,395   (31.9)  
 2 +    47   (38.5)   17,839   (29.3)  
Parity, n (%)b
 0   51   (41.8)   29,490   (48.4)   0.1
 1   53   (43.4)   20,913   (34.4)  
 2 +    18   (14.8)   9532   (15.7)  
Gestational age at delivery, mean (SD)   280   (7.70)   NA  
Method of delivery, n (%)b
 Acute CS   9   (7.4)   6520   (10.7)   0.4
 Planned CS   14   (11.5)   5548   (9.1)  
 Vacuum extractionc   3   (2.5)   NA  
 Vaginal   96   (78.7)   48,803   (80.2)  
Infant sex, n (%)b
 Boy   63   (51.6)   31,166   (51.2)   0.9
 Girl   59   (48.4)   29,705   (48.8)  
Infant weight, g, mean, SDa   3592   (457)   3474   (609)   0.005
Apgar <7 at 5 min, n (%)   0   (100.0)   NA  
aT-test, bchi-squared test, ccensored from test. SD, standard deviation; n (%), column % per level; NA, not applicable.
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Table 3: Reference intervals per 2 weeks’ gestation.
Analyte (abbreviation), 
conventional range, unit, outliers
  Weeks’ 
gestation
  n  
 
Reference interval  
 
90% CI for the reference interval 
percentiles
2.5 percentile   97.5 percentile 2.5 percentile   97.5 percentile
Human chorionic gonadotropin 
(hCG) total, U/L
  <6   69   226   32,660   0   364   21,755   48,387
  6–8   120   10,622   161,144   5422   15,571   124,479   200,000
  8–10   117   45,180   200,000   36,685   68,721   200,000   207,915
  10–12   93   36,709   171,645   34,758   38,585   143,290   194,872
  >12   63   22,314   143,568   14,363   26,780   118,943   181,980
Human chorionic gonadotropin 
(fhCG) free, U/L
  <6   70   0.1   27.1   0.0   0.2   26.0   32.8
  6–8   121   7.9   155.3   3.8   11.2   127.3   206.9
  8–10   118   20.5   223.8   10.8   31.0   120.6   257.1
  10–12   93   21.0   211.6   18.9   25.7   201.0   265.3
  >12   63   11.4   118.4   7.8   13.5   86.5   155.0
Pregnancy-associated plasma 
protein A (PAPP-A), U/L
  <6   70   0.00   0.24   0.00   0.01   0.00   0.46
  6–8   121   0.02   0.46   0.01   0.02   0.36   3.48
  8–10   118   0.13   1.87   0.12   0.19   0.00   2.19
  10–12   93   0.46   5.79   0.33   0.54   0.34   6.60
  >12   63   0.90   15   0.45   0.96   13   19
Estradiol (E2)   <6   69   0.4   3.0   0.3   0.5   2.4   3.6
0.25–1.2 nmol/L (luteal phase)   6–8   120   0.8   5.8   0.7   0.9   5.1   6.3
  8–10   119   1.0   8.6   0.4   1.3   7.1   10
  10–12   90   1.5   10   0.9   2.0   9.6   12
  >12   54   2.2   10   1.5   2.4   9.7   11
Progesterone (P4), total   <6   70   21   138   13   26   123   152
20–100 nmol/L (luteal phase)   6–8   120   27   147   20   30   118   154
  8–10   118   28   156   23   31   144   185
  10–12   92   38   177   28   48   173   206
  >12   59   53   172   48   54   161   187
Cancer antigen 125 (CA125)   <6   70   7   170   4   7   131   254
<35 U/mL   6–8   120   8   98   4   14   82   119
  8–10   118   8   69   5   11   32   76
  10–12   94   6   50   4   8   32   59
  >12   63   6   47   4   7   38   62
Albumin (ALB)   <6   70   36   48   34   36   47   50
37–48 g/L   6–8   119   36   46   35   37   44   46
  8–10   118   34   45   33   35   43   46
  10–12   94   32   43   31   33   43   44
  >12   63   31   42   29   31   42   43
Alkaline phosphatase (ALP)   <6   69   33   108   25   43   106   125
37–106 U/L   6–8   118   33   96   29   39   79   111
  8–10   118   32   117   29   37   108   148
  10–12   94   32   101   29   33   90   124
  >12   63   28   127   23   28   117   164
Alanine transaminase (ALT)   <6   69   10   49   9   10   30   63
8–46 U/L   6–8   117   8   43   7   10   31   53
  8–10   118   7   53   6   8   40   70
  10–12   94   7   38   6   7   28   50
  >12   63   6   28   5   7   27   31
Aspartate transaminase (AST)   <6   70   9   33   8   10   31   42
13–37 U/L   6–8   118   9   24   9   10   20   27
  8–10   118   8   26   7   9   24   30
  10–12   94   8   26   7   10   21   31
  >12   63   9   19   8   9   19   21
Lactate dehydrogenase (LDH)   <6   69   109   205   103   118   136   235
103–204 U/L   6–8   118   109   175   104   114   152   187
One outlier removed   8–10   118   105   172   100   136   164   176
  10–12   94   98   184   83   102   175   202
  >12   63   83   186   57   110   185   208
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Analyte (abbreviation), 
conventional range, unit, outliers
  Weeks’ 
gestation
  n  
 
Reference interval  
 
90% CI for the reference interval 
percentiles
2.5 percentile   97.5 percentile 2.5 percentile   97.5 percentile
Bilirubin (BIL) total   <6   70   4   29   4   4   29   39
5–24 μmol/L   6–8   118   4   20   3   4   11   24
  8–10   118   3   20   3   4   12   24
  10–12   94   3   21   2   3   19   25
  >12   63   3   16   3   3   12   21
Cholesterol (CHOL) total   <6   70   2.6   6.6   2.2   2.8   5.9   7.7
3.4–6.9 mmol/L   6–8   117   2.8   5.5   2.7   3.4   5.4   5.8
  8–10   118   2.9   5.9   2.6   3.3   3.9   6.2
  10–12   94   3.2   6.4   3.0   3.4   4.9   6.9
  >12   63   3.0   8.0   2.4   3.1   7.7   9.9
Low-density lipoprotein (LDL)   <6   70   1.1   4.9   0.8   1.5   4.3   5.7
1.4–4.7 mmol/L   6–8   117   1.0   3.9   0.5   1.5   3.8   4.4
  8–10   118   1.1   4.2   0.9   1.5   2.6   4.7
  10–12   94   1.5   4.3   1.3   1.7   2.6   4.5
  >12   63   1.1   6.1   0.5   1.7   6.0   8.1
High-density lipoprotein (HDL)   <6   70   1.1   2.3   1.0   1.1   2.1   2.5
1.0–2.6 mmol/L   6–8   118   1.0   2.5   0.9   1.2   1.9   2.8
  8–10   118   1.1   2.6   1.0   1.2   1.6   2.8
  10–12   94   1.1   3.0   0.9   1.2   2.4   3.3
  >12   63   1.2   3.2   1.0   1.3   2.6   3.8
Triglyceride (TRIG)   <6   70   0.42   2.3   0.40   0.44   1.5   3.0
0.47–2.6 mmol/L   6–8   118   0.43   2.3   0.39   0.50   1.8   2.7
  8–10   118   0.46   3.1   0.33   0.59   3.0   3.8
  10–12   94   0.56   2.4   0.49   0.60   2.4   2.7
  >12   63   0.70   2.9   0.64   0.70   2.5   3.5
Sodium (Na)   <6   70   132   143   130   135   140   150
137–145 mmol/L   6–8   120   134   141   133   135   140   141
  8–10   117   133   141   132   134   140   141
  10–12   94   134   141   134   135   140   141
  >12   63   135   142   133   134   139   146
Potassium (K)   <6   69   3.3   4.4   3.1   3.3   4.1   4.6
3.6–4.6 mmol/L   6–8   120   3.6   4.3   3.4   3.6   4.2   4.5
  8–10   117   3.5   4.4   3.4   3.6   4.3   4.5
  10–12   94   3.5   4.4   3.5   3.6   4.3   4.5
  >12   63   3.4   4.3   3.3   3.4   4.2   4.4
Creatinine (CREA)   <6   70   42   68   37   43   67   71
51–84 μmol/L   6–8   118   43   67   42   48   61   69
  8–10   118   39   66   37   43   60   70
  10–12   94   40   64   40   41   62   67
  >12   63   39   64   36   40   59   68
Urea nitrogen (BUN)   <6   70   2.1   6.3   1.8   2.4   5.7   6.6
2.7–6.4 mmol/L   6–8   118   2.2   5.7   2.0   2.2   5.3   6.0
  8–10   118   2.1   5.6   1.9   2.5   5.3   6.1
  10–12   94   2.0   5.5   1.8   2.0   4.2   5.6
  >12   63   1.9   5.2   1.6   2.1   4.9   5.6
Uric acid (URIC)   <6   70   0.12   0.30   0.10   0.12   0.27   0.34
0.15–0.35 mmol/L   6–8   118   0.10   0.27   0.08   0.10   0.24   0.29
  8–10   118   0.10   0.26   0.09   0.12   0.19   0.28
  10–12   94   0.09   0.25   0.08   0.10   0.22   0.27
  >12   63   0.10   0.26   0.09   0.10   0.24   0.28
Thyroxine (T4) total   <6   70   67   118   62   70   118   124
60–140 nmol/L   6–8   120   71   142   66   77   126   166
  8–10   118   79   151   71   86   150   159
  10–12   94   77   164   61   80   144   174
  >12   63   80   167   66   89   164   182
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Analyte (abbreviation), 
conventional range, unit, outliers
  Weeks’ 
gestation
  n  
 
Reference interval  
 
90% CI for the reference interval 
percentiles
2.5 percentile   97.5 percentile 2.5 percentile   97.5 percentile
Thyroxine (fT4) free   <6   67   11   17   11   12   17   18
12–21 pmol/L   6–8   112   11   19   11   12   18   20
  8–10   114   11   18   10   12   15   18
  10–12   90   11   18   11   11   18   20
  >12   63   11   17   10   11   17   18
Triiodothyronine (T3)   <6   70   1.3   2.6   1.2   1.3   2.4   3.2
1.1–2.5 nmol/L   6–8   120   1.3   2.4   1.3   1.4   2.4   2.5
  8–10   118   1.5   2.9   1.4   1.6   2.7   3.3
  10–12   94   1.5   2.9   1.4   1.6   2.7   3.2
  >12   63   1.5   3.0   1.3   1.5   3.0   3.3
Triiodothyronine (fT3), free   <6   67   3.6   6.2   3.2   3.8   6.2   6.6
3.9–6.8 pmol/L   6–8   112   3.7   6.0   3.3   3.9   5.7   6.4
  8–10   113   3.5   5.6   3.2   3.7   5.6   5.9
  10–12   90   3.8   5.4   3.7   4.1   4.9   5.5
  >12   63   3.7   5.2   3.4   3.7   5.2   5.4
Thyroid stimulating hormone (TSH)   <6   70   0.68   5.29   0.34   0.86   4.72   6.42
0.30–4.00 mU/L   6–8   117   0.35   4.05   0.30   0.40   1.82   4.55
  8–10   117   0.10   4.14   0.03   0.14   3.56   5.00
  10–12   94   0.08   5.76   0.00   0.12   4.28   8.17
  >12   63   0.37   7.41   0.22   0.48   3.89   11.5
Iron (IRON), free   <6   69   5   26   3   7   25   29
9–34 μmol/L   6–8   118   7   30   4   9   22   32
1 outlier removed   8–10   118   4   33   3   6   32   38
  10–12   94   5   34   3   6   28   40
  >12   63   4   29   1   4   27   32
Ferritin (FTL)   <6   70   13   141   7   21   124   154
15–200 μg/L   6–8   120   17   146   6   20   124   171
  8–10   118   14   149   9   15   103   172
  10–12   94   12   161   6   14   153   179
  >12   63   9   109   1   9   76   138
C-reactive protein (CRP)   <6   70   2.9   19   2.9   2.9   12   22
<3 mg/L   6–8   118   2.9   18   2.9   2.9   8.5   30
  8–10   118   2.9   22   2.9   2.9   14   44
  10–12   94   2.9   17   2.9   2.9   13   34
  >12   63   2.9   31   2.9   2.9   16   32
Table 3 (continued)
growth restriction. However, our data display great vari-
ability in what was needed to maintain the pregnancy, 
demonstrated by one participant who had all three 
proteins consistently below the 2.5th percentile limit 
throughout the first trimester. Despite this, the preg-
nancy was uneventful and ended up in the delivery of a 
healthy and normal-weight neonate. This illustrates the 
difference between RI and establishing clinically appli-
cable decision limits, for example, “lowest values associ-
ated with live birth”. Accordingly, diagnostics based on 
our reported limits should be cautiously done and serial 
measurements are warranted [27].
As expected, total T4 and T3 increased while the levels 
of the free hormones were unchanged. Increased total 
concentrations are caused by the well-known increase 
of thyroglobulin binding protein (TBG) beginning at the 
time of placentation [28–30]. The TSH concentration was 
inversely linked to hCG attributed to their structural simi-
larities; they share the same alpha subunit causing cross 
reactivity at the TSH receptor. Therefore, hCG, when in 
abundance, acts in a thyrotrophic manner in the pituitary 
and produces a negative feedback [31].
Another feature of Figure 2 is the luteoplacental shift 
traditionally defined as the onset of placental steroido-
genesis of P4 and E2. This juncture is clinically important, 
especially in reproductive endocrine therapy of infer-
tile women seeking fertility treatment. Theoretically, the 
onset of endogenous placental sex steroid production is 
the earliest time when exogenous steroid administration 
may be withdrawn. The exact timing of this shift has been 
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debated. In 1990, Devroey et al. [32] reported a significant 
E2 and P4 rise by 7 and 9 weeks’ gestation, respectively, 
examining 18 pregnancies from oocyte donation in agonal 
women. One year later, Scott et al. [33] performed a similar 
study and observed similar elevations already at 6 and 
7 weeks’ gestation, respectively. These studies provided a 
near-optimal in vivo model of placental steroidogenesis as 
the endogenous contribution from the corpus luteum was 
unavailable. Nonetheless, as the developing conceptus 
is dependent on the corpus luteum, these protocols had 
to supply exogenous sex steroids that potentially disturb 
the estimation of onset timing. Conversely, our setup dis-
played the continuum of E2 and P4 levels attributed by 
both the corpus luteum and the developing placenta in a 
non-supplemented pregnancy. Therefore, the exact origin 
of steroid production cannot be determined. As shown in 
Figure 2, P4 increased almost linearly while E2 elevated 
more rapidly from 6 to 8 weeks’ gestation. We decided to 
define statistical significance as the time when 90% CIs of 
the calculated RI limits (2.5th or 97.5th) were decreased or 
increased compared with the non-pregnant equivalents. 
Therefore, our results support the notion of increased sex 
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Figure 2: Scatter plot of the eight analytes with the most prominent changes early in pregnancy.
Every observed value and smoothed percentiles (red: 97.5th; maroon: 2.5th; green: 25–75th and yellow: the median) are plotted to the 
gestational age in weeks 4–14. Vertical lines mark the timing of the 2.5th (maroon) and the 97.5th (red) centile of the calculated reference 
interval becoming statistically significantly different from the conventional limits if available (orange boxes).
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steroid production around week 6 (P4 97.5th and 2.5th 
significantly increased by 4.5 and 5.9  weeks’ gestation, 
respectively), probably attributed by the placental onset 
and seemingly more pronounced in E2 (E2 97.5th and 2.5th 
were significantly increased by 4.5 and 4.7 weeks’ gesta-
tion, respectively).
CA125 is usually associated with ovarian cancer diag-
nostics. In pregnancy, CA125 is expressed by the decidual 
cells and secreted to circulation in the first trimester due 
to decidual invasion by the trophoblast during placenta-
tion [34]. Therefore, CA125 becomes a marker of placenta-
tion also seen in Figure 2, as the values from 4 to 8 weeks’ 
gestation exceeds the ovarian cancer diagnostic cutoff of 
35 U/mL. Interestingly, the upper limit was significantly 
increased already at 4.5 weeks’ but returned to non-preg-
nant limits after 11 weeks. This finding warrants clinical 
vigilance towards interpretation of CA125 in the early first 
trimester and support the previously shown potential of 
CA125 as a first trimester biomarker [35]. As expected, the 
theoretical lower limit of 0 in the CA125 non-pregnant RIs 
was exceeded in all observations.
Renal
Pregnancy has a major impact on kidney function and 
fluid/salt balance and the biomarkers Na, K, URIC, CREA 
and BUN reflect these physiologically changes in the 
pregnant body throughout the first trimester. Follow-
ing progesterone and relaxin-mediated decreased sys-
temic vascular resistance from the corpus luteum, also 
renal vasculature is relaxed and allows increased blood 
flow and glomerular filtration rate (GFR) [36, 37]. Conse-
quently, as seen in Figure 2 and Supplementary Figure 1, 
CREA (97.5th and 2.5th percentile significantly decreased 
throughout the observation and by 4.5 weeks’ gestation, 
respectively), URIC and BUN started at a low value and 
decreased with gestation [8–10]. Furthermore, the hyperv-
olemic-hypoosmolar-characteristic state of pregnancy [36, 
37] was seen by the stable and unchanged RIs of sodium 
and potassium – both with at least the 2.5th percentile at 
a lower level compared with the non-pregnant references.
Liver
There was a steady increase in serum lipids throughout 
the first trimester. As the fetus develops, the triglycerides 
increase as metabolic changes prioritize the develop-
ment of fatty stores during the first trimester to satisfy 
maternal energy needs later in pregnancy. Additionally, 
the increased production of sex steroids necessitates 
increased CHOL, HDL and LDL levels as precursor sub-
strates [37, 38]. Compared with conventional limits the 
differences were marginal. Nonetheless, our data clearly 
illustrate that the well-known gestational changes 
already can be visualized from the beginning of the preg-
nancy. Also evident at this stage, was the well-known 
reduction in albumin during the first trimester [9, 10]. 
The albumin RIs were initially within conventional limits 
[39], but already from about 5.5 weeks’ gestation the 2.5th 
percentile was lower than the conventional equivalent 
(Figure  2) and significantly different at 6.8  weeks. This 
decrease continued throughout the first trimester before 
ending up in a range >12 weeks (31–42 g/L) comparable 
to the work by Klajnbard et  al. [8] who reported an RI 
of 32–43 g/L by 13–20  weeks’ gestation. Although their 
work constitutes the most thorough investigation of the 
Danish population and serves as the reference for preg-
nant women in most Danish obstetric consultations, the 
authors were not able to sample individuals from the first 
trimester and an RI is therefore unavailable. In another 
report from the Scandinavian population, Larsson et al. 
[9] also found ALB values from 7 to17 weeks’ gestation of 
32–43 g/L. We argue, that this 10-week period probably 
contained a higher and non-pregnant-like ALB RI in the 
earliest part of the first trimester and illustrate the added 
precision that may arise from scrutinizing references in 
smaller intervals.
Multiple mechanisms such as hemodilution [9], 
increased catabolism [8] and maximized pregnancy-
dependent reprogramed liver synthesis [40] have been 
suggested to cause the decrease in albumin concentra-
tion with gestation. Our early declining values support 
the theory of albumin being increasingly catabolized for 
the development of the fetal unit at a rate that exceeds the 
normal capacity for liver synthesis. From gestational week 
5.5 some hemodilution is possible, although this tradition-
ally has not been observed before at least 6 weeks’ gesta-
tion [41]. Additionally, bigger molecules such as HDL are 
unchanged or slightly increasing within the period as also 
shown by Klajnbard et  al. [8]. Supporting the view that 
these changes are caused by reprograming of liver synthe-
sis during pregnancy is the fact that liver cell turnover, as 
evaluated by the ALT, AST and LDH, was stable and unaf-
fected (Supplementary Figure 1). Conjugation and excre-
tion of bilirubin also seemed unaffected (Supplementary 
Figure 1). The lower 2.5th percentile reference limit of AST, 
ALP and BIL was interpreted as a difference between the 
age of our study population (22–38 years) and the conven-
tional value population. These mostly originated from the 
Nordic Reference Interval Project (NORIP) [39] providing 
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comparable non-pregnant intervals specified by female 
gender, ethnicity and societal factors such as the dietary 
intake in the Nordic countries, but pooled values from 
participants from 18 to 49 years of age.
Inflammation
CRP has been intensively researched in pregnancy with a 
general tendency of increased values by gestation [8, 42, 
43]. Supported by our findings, values vary immensely, 
and any meaningful interpretation needs to be closely cor-
related to clinical development of symptoms.
Strengths and limitations
The study population was a well-characterized and 
homogenous cohort of Caucasian women with complete 
follow-up until delivery. Hence, the reported RIs give 
a solid base for clinical application in populations of 
this demography. As seen in Table 2, compared with the 
Danish birth cohort of 2017, our sample represents the 
nationwide numbers rather accurately with minor differ-
ences of negligible significance. All reported RIs follow 
the recommendations of the IFCC [11, 21], albeit with few 
samples in the extreme <6 and >12  weeks’ gestational 
intervals. These values should therefore be cautiously 
interpreted, while they simultaneously provide a rare 
view at naturally conceived pregnancies <6 weeks’ gesta-
tion. The prospective design allowed for CRL-determined 
gestational age even at the earliest available samples. All 
analyzed samples were handled by the same investigator 
and followed the directions of the UK biobank [44], opti-
mizing the integrity and precision of the reported values. 
Ideally, we would have provided a complete first trimester 
material of all parameters investigated by Klajnbard et al. 
[8] Unfortunately, our laboratory setup was unable to do 
full-blood analyses, for example, hematological analytes. 
Future research might focus on procuring these missing 
quantities in the early part of the first trimester.
Conclusions
Collectively, this study reports gestational age-specific RIs 
from 4 to 12 weeks’ gestation in 29 commonly used ana-
lytes applicable to clinicians caring for pregnant women. 
Our findings confirm the well-known fact that pregnancy 
alter non-pregnant RI. This should be considered already 
in the first trimester.
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